'Gilead' C-Level Executives Simultaneously Sell Company Shares According to Pre-Established Plan

Gilead Sciences, Inc. (NASDAQ: GILD) announced that its Chief Commercial Officer and Chief Financial Officer each sold 3,000 shares of the company’s common stock on January 15 at an average price of $124.31 per share, securing roughly $370,000 in cash apiece (approximately KRW 480 million).

Both transactions were executed under pre-established Rule 10b5-1 trading plans, and each executive still retains around 100,000 shares, maintaining alignment with shareholder interests.

Last December, Gilead disclosed plans for its management team to present to major investors at the J.P. Morgan Healthcare Conference on January 12, 2026, and in its Q3 2025 earnings release it reaffirmed its growth strategy for its viral disease and oncology portfolios.

In December 2025, Gilead also entered into an agreement with the U.S. government to lower the cost of certain medicines— including HIV, hepatitis, and COVID-19 treatments—and announced significant facility investment plans in the United States.

Headquartered in Foster City, California, Gilead is a leading biopharmaceutical company focused on developing and delivering treatments for HIV, hepatitis B and C, COVID-19, cancer, and inflammatory diseases, and has maintained a strong antiviral leadership position for over 30 years.